Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 411-416

  Giachelia, Manuela ^a   Voso, Maria Teresa ^a   Tisi, Maria Chiara ^a   Martini, Maurizio ^a   Bozzoli, Valentina ^a   Massini, Giuseppina ^a   D'Al, Francesco ^a   Larocca, Luigi Maria ^a   Leone, Giuseppe ^a   Hohaus, Stefan ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cytokine plasma levels; Diffuse large B cell lymphoma; NF B; Polymorphism; Prognosis

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; METHYLPREDNISOLONE; MITOXANTRONE; NUCLEAR FACTOR KAPPA B1; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE DELETION; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MITOXANTRONE; NEOPLASM PROTEINS; NF-KAPPA B P50 SUBUNIT; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISONE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SEQUENCE DELETION; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84856569819     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.621566     Document Type: Article

References (46)

1. Lossos IS, Morgensztern D. Prognostic biomarkers in diff use large B-cell lymphoma. J. Clin. Oncol. 2006;24:995-1007. (Pubitemid 46638855)
2. Lenz G, Wright G, Dave SS.et al. Stromal gene signatures in large- B-cell lymphomas. N. Engl. J. Med. 2008;359:2313-2323.
3. Linderoth J, Edé n P, Ehinger M.et al. Genes associated with the tumour microenvironment are diff erentially expressed in cured versus primary chemotherapy-refractory diff use large B-cell lymphoma. Br. J. Haematol. 2008;141:423-432. (Pubitemid 351550546)
4. S eymour J, Talpaz M, Cabanillas F.et al. Serum interleukin-6 levels correlate with prognosis in diff use large-cell lymphoma. J. Clin. Oncol. 1995;13:575-582.
5. B lay J-Y, Burdin N, Rousset F.et al. Serum interleukin-10 in non Hodgkins lymphoma: A prognostic factor. Blood 1993;82:2169-2174. (Pubitemid 23294002)
6. S tasi R, Zinzani PL, Galieni P.et al. Prognostic value of serum IL-10 and IL-2 receptor levels in aggressive non-Hodgkins lymphoma. Br. J. Haematol. 1994;88:770-777. (Pubitemid 24375792)
7. C ortes JE, Talpaz M, Cabanillas F.et al. Serum levels of interleukin- 10 in patients with diff use large cell lymphoma: Lack of correlation with prognosis. Blood 1995;85:2516-2520.
8. V oorzanger N, Touitou R, Garcia E.et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkins lymphoma cells and act as cooperative growth factors. Cancer Res. 1996;56:5499-5505. (Pubitemid 27011386)
9. F abre-Guillevin E, Tabrizi R, Coulon V.et al. Aggressive non- Hodgkins lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006;47:603-611.
10. S mith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009;20:43-59.
11. L an Q, Zheng T, Rothman N.et al. Cytokine polymorphisms in the Th 1/Th 2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101-4108. (Pubitemid 43726819)
12. Domingo-Dom é nech E, Benavente Y, Gonz á lez-Barca E.et al. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 2007;92:1475-1481. (Pubitemid 350144122)
13. L ech-Maranda E, Baseggio L, Charlot C.et al. Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 2007;48:2235-2238. (Pubitemid 350091067)
14. C hen Y, Zheng T, Lan Q.et al. Cytokine polymorphisms in Th 1/Th 2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011;117:585-590.
15. C ordano P, Lake A, Shield L.et al. Eff ect of IL-6 promoter polymorphism on incidence and outcome in Hodgkins lymphoma. Br. J. Haematol. 2005;128:493-495. (Pubitemid 40283166)
16. H ohaus S, Giachelia M, Di Febo A.et al. Polymorphism in cytokine genes as prognostic markers in Hodgkins lymphoma. Ann. Oncol. 2007; 18:1376-1381. (Pubitemid 47305013)
17. K ube D, Hua TD, von Bonin F.et al. Eff ect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkins lymphoma: An exploratory study. Clin. Cancer Res.. 2008;14:3777-3784.
18. H abermann TM, Wang SS, Maurer MJ.et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diff use large B-cell lymphoma patients in the pre-rituximab era. Blood 2008;112:2694-2702.
19. L ech-Maranda E, Baseggio L, Bienvenu J.et al. Interleukin-10 gene promoter polymorphisms infl uence the clinical outcome of diff use large B-cell lymphoma. Blood 2004;103:3529-3534. (Pubitemid 38525688)
20. C erhan JR, Liu-Mares W, Fredericksen ZS.et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkins lymphoma. Cancer Epidemiol Biomarkers Prev 2008;17:3161-3169.
21. R ossi D, Rasi S, Franceschetti S.et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diff use large B-cell lymphoma treated with R-CHOP21. Leukemia 2009;23:1118-1126.
22. R ossi D, Rasi S, Di Rocco A.et al. Th e host genetic background of DNA repair mechanisms is an independent predictor of survival in diff use large B-cell lymphoma. Blood 2011;117:2405-2413.
23. L enz G, Staudt LM. Aggressive lymphomas. N. Engl. J. Med. 2010;362:1417-1429.
24. K arban AS, Okazaki T, Panhuysen CI.et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45. (Pubitemid 38072133)
25. A ndersen V, Christensen J, Overvad K.et al. Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer 2010;10:484.
26. R iemann K, Becker L, Struwe H.et al. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superfi cial bladder cancer. Int J Clin Pharmacol Th er 2007;45:423-430. (Pubitemid 47243938)
27. B u H, Rosdahl I, Sun XF.et al. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res. Clin. Oncol. 2007;133:859-866. (Pubitemid 350218912)
28. Hohaus S, Giachelia M, Massini G.et al. Clinical signifi cance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res 2009;33:1352-1356.
29. Casasnovas RO, Mounier N, Brice P.et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkins lymphoma: A study from the Groupe d ' Etude des Lymphomes de l ' Adulte. J. Clin. Oncol. 2007;25:1732-1740. (Pubitemid 46797954)
30. S orá F, Piccirillo N, Chiusolo P.et al. Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: A salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma. Cancer 2006;106:859-866. (Pubitemid 43238453)
31. Sehn LH, Berry B, Chhanabhai M.et al. Th e revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diff use large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. (Pubitemid 46348180)
32. Z iepert M, Hasenclever D, Kuhnt E.et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20- B-cell lymphoma in the rituximab era. J. Clin. Oncol. 2010;28:2373-2380.
33. Haddy N, Sass C, Maumus S.et al. Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur. J. Hum Genet 2005;13:109-117.
34. Fishman D, Faulds G, Jeff ery R.et al. Th e eff ect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998;102:1369-1376. (Pubitemid 28467565)
35. Kilpinen S, Hulkkonen J, Wang XY.et al. Th e promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw 2001;12:62-68. (Pubitemid 32281191)
36. Veres A, Proh á szka Z, Kilpinen S.et al. Th e promoter polymorphism of the IL-6 gene is associated with levels of antibodies to 60-kDa heatshock proteins. Immunogenetics 2002;53:851-856. (Pubitemid 34211799)
37. Hegedus CM, Skibola CF, Bracci P.et al. Screening the human serum proteome for genotype-phenotype associations: An analysis of the IL6 -174G- C polymorphism. Proteomics 2007;7:548-557. (Pubitemid 46362618)
38. Taudorf S, Krabbe KS, Berg RM.et al. Common studied polymorphisms do not aff ect plasma cytokine levels upon endotoxin exposure in humans. Clin Exp Immunol 2008;152:147-152. (Pubitemid 351347563)
39. L atiano A, Palmieri O, Valvano MR.et al. Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in infl ammatory bowel disease: A meta-analysis. Infl amm Bowel Dis 2007;13:1212-1219. (Pubitemid 47603099)
40. Riemann K, Becker L, Struwe H.et al. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 2006;16:783-788. (Pubitemid 44632292)
41. Vangsted AJ, Klausen TW, Gimsing P.et al. A polymorphism in NFKB1 is associated with improved eff ect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica 2009;94:1274-1281.
42. E nnishi D, Yokoyama M, Terui Y.et al. Soluble interleukin-2 receptor retains prognostic value in patients with diff use large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann. Oncol. 2009;20:526-533.
43. Mounier N, Briere J, Gisselbrecht C.et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diff use large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284. (Pubitemid 36857789)
44. Ott G, Ziepert M, Klapper W.et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifi er predicts outcome in diff use large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-4925.
45. Salles G, de Jong D, Xie W.et al. Prognostic signifi cance of immunohistochemical biomarkers in diff use large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070-7078.
46. P reti HA, Cabanillas F, Talpaz M.et al. Prognostic value of serum interleukin-6 in diff use large-cell lymphoma. Ann Intern Med 1997;127:186-194. (Pubitemid 27332536)